Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Original Article

Bariatric intervention improves metabolic dysfunction-associated steatohepatitis in patients with obesity: A systematic review and meta-analysis

Juchul Hwang, Hyeyoung Hwang, Hyunjae Shin, Bo Hyun Kim, Seong Hee Kang, Jeong-Ju Yoo, Mi Young Choi, Dong eun Lee, Dae Won Jun, Yuri Cho

Clin Mol Hepatol. 2024;30(3):561-576. Published online June 3, 2024

DOI: https://doi.org/10.3350/cmh.2023.0384

View: 2311 Download: 120 Web of Science: 1 Crossref: 1

Editorial

The gene expression signature of metabolic dysfunction- associated steatotic liver disease from a multiomics perspective

Carlos Jose Pirola, Silvia Sookoian

Clin Mol Hepatol. 2024;30(2):174-176. Published online February 5, 2024

DOI: https://doi.org/10.3350/cmh.2024.0082

View: 2302 Download: 71 Web of Science: 1 Crossref: 1

Correspondence

Correspondence to editorial on “Macrophage ATG16L1 expression suppresses metabolic dysfunction-associated steatohepatitis progression by promoting lipophagy”

Qi Wang, Qingfa Bu, Haoming Zhou, Ling Lu

Received June 24, 2024 Accepted July 5, 2024

DOI: https://doi.org/10.3350/cmh.2024.0470 [Epub ahead of print]

View: 397 Download: 29

Original Article

DNA methylome analysis reveals epigenetic alteration of complement genes in advanced metabolic dysfunction-associated steatotic liver disease

Amal Magdy, Hee-Jin Kim, Hanyong Go, Jun Min Lee, Hyun Ahm Sohn, Keeok Haam, Hyo-Jung Jung, Jong-Lyul Park, Taekyeong Yoo, Eun-Soo Kwon, Dong Hyeon Lee, Murim Choi, Keon Wook Kang, Won Kim, Mirang Kim

Received April 9, 2024 Accepted July 24, 2024

DOI: https://doi.org/10.3350/cmh.2024.0229 [Accepted]

View: 816 Download: 177

Correspondence

Correspondence on Letter regarding “A complement to epigenetics in MASLD”

Amal Magdy, Hee-Jin Kim, Won Kim, Mirang Kim

Received September 6, 2024 Accepted September 9, 2024

DOI: https://doi.org/10.3350/cmh.2024.0761 [Accepted]

View: 196 Download: 12

1 |

Viewed By 5163	MAFLD: How is it different from NAFLD?
Viewed By 4908	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Viewed By 4875	Evaluating the therapeutic efficacy of NAD supplementation in management of metabolic dysfunction-associated steatotic liver disease: Key considerations
Viewed By 4604	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Viewed By 4576	Global incidence and prevalence of nonalcoholic fatty liver disease

Cited By 219	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Cited By 155	Global incidence and prevalence of nonalcoholic fatty liver disease
Cited By 134	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Cited By 119	MAFLD: How is it different from NAFLD?
Cited By 96	Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach

Search